Deuruxolitinib Hair Regrowth Dose Breakthrough: Phase 2 Trial Shows 8 mg Twice Daily Beats 16 mg Once Daily for Severe Alopecia Areata

A new Phase 2 alopecia areata study has revealed something extremely practical about JAK-inhibitor hair regrowth: dose timing may matter almost as much as total daily dose.

The trial compared two ways of giving the same total daily amount of deuruxolitinib, a JAK1/2 inhibitor used for severe alopecia areata research: 8 mg twice daily versus 16 mg once daily. By week 24, the twice-daily schedule produced much stronger scalp-hair improvement.

The headline result was a mean relative SALT score improvement of 46.4% with 8 mg twice daily, compared with 18.0% with 16 mg once daily. That is a striking difference for the same total daily dose.

This is not a do-it-yourself dosing recommendation. Deuruxolitinib is a systemic immune drug and must be prescribed and monitored by a clinician. But the study is important because it suggests that maintaining steadier JAK pathway suppression across the day may be critical for reversing autoimmune follicle attack.

What Is It and How Does It Work?

Deuruxolitinib is an oral Janus kinase inhibitor, usually called a JAK inhibitor. It targets JAK1 and JAK2 signaling pathways used by inflammatory cytokines.

Alopecia areata is an autoimmune hair-loss disease. The immune system attacks the hair follicle, disrupts the follicle’s immune privilege, and can push follicles into sudden shedding or failed growth. Unlike androgenetic alopecia, the follicle is often still alive, but it is being held under immune pressure.

The proposed mechanism is blocking immune cytokine signals that keep follicles under attack:

1. The disease signal: inflammatory cytokines activate JAK-STAT pathways around the follicle.
2. The follicle effect: immune cells disrupt normal anagen growth and can cause patchy or complete hair loss.
3. The treatment: deuruxolitinib reduces JAK1/2 signaling, weakening the autoimmune attack.
4. The visible result: if immune pressure falls enough, living follicles may resume hair production.

The new study does not simply ask whether deuruxolitinib works. It asks how the dose should be delivered across the day to get better hair regrowth.

The Science: 8 mg Twice Daily Beat 16 mg Once Daily

The study was a Phase 2 randomized trial in adults with severe alopecia areata. It included 57 patients, with a mean age of 40.1 years, and 66.7% of participants were female.

Patients were randomized to one of two schedules:

• Deuruxolitinib 8 mg twice daily
• Deuruxolitinib 16 mg once daily

The primary endpoint was relative change from baseline in Severity of Alopecia Tool score, known as SALT score, at week 24. SALT measures scalp hair loss from 0 to 100, where higher scores mean more hair loss.

The results favored the twice-daily schedule:

• 8 mg twice daily: 46.4% mean relative SALT improvement at week 24
• 16 mg once daily: 18.0% mean relative SALT improvement at week 24

The paper also reports that a greater proportion of patients on 8 mg twice daily achieved SALT score of 20 or less and SALT score of 10 or less, both clinically meaningful thresholds for major scalp-hair recovery.

Treatment-emergent adverse events were described as mild or moderate in severity, but the study was small. Larger studies are still needed to fully define safety and the best dosing strategy.

Why This Could Be a Big Deal for Alopecia Areata

Many people think of drug dosing only in terms of total milligrams per day. This study shows why that can be too simplistic for immune signaling diseases.

In alopecia areata, the immune system is not attacking follicles for one moment and then stopping. Cytokine signaling can be persistent. If the drug level falls too low before the next dose, the inflammatory loop may regain momentum.

That may explain why splitting the same total daily dose into two administrations performed better. A twice-daily schedule may provide more sustained pathway control across 24 hours.

This matters because severe alopecia areata treatment often requires balancing three things:

• enough immune suppression to allow follicles to regrow,
• enough safety margin to reduce infection and systemic-risk concerns,
• enough convenience that patients can actually follow the regimen.

The study suggests that smarter scheduling, not just bigger dosing, may improve that balance.

When Will It Be Available?

Deuruxolitinib is already known in the alopecia areata field, and Leqselvi is an approved deuruxolitinib product for severe alopecia areata in some regulatory settings. Availability depends on country, labeling, prescribing rules, and safety requirements.

This Phase 2 dose-optimization paper is still useful because it helps explain why one dosing schedule may outperform another even when the total daily dose is the same.

The next research steps should include:

• larger dose-comparison trials,
• longer safety monitoring,
• relapse data after stopping or reducing dose,
• comparisons with other approved JAK inhibitors,
• and analysis of which patients respond fastest or most completely.

Because JAK inhibitors can affect infection risk, blood counts, lipids, liver enzymes, and other systemic safety markers, this is a dermatologist-managed treatment category.

How You Can Benefit From This Research Now

If you have severe alopecia areata, the practical lesson is not to adjust dosing yourself. The lesson is to ask better questions with your clinician.

1. Ask whether your treatment goal is disease control or cosmetic regrowth. Those are related, but not identical, and dosing strategy may matter.
2. Ask why a specific schedule was chosen. Once-daily dosing may be convenient, but this study suggests twice-daily exposure can matter for deuruxolitinib response.
3. Track SALT score over time. Objective scoring helps determine whether the immune attack is truly quieting.
4. Expect monitoring. JAK inhibitors are powerful systemic medicines, not supplements.
5. Plan for maintenance. Alopecia areata often relapses when immune control is withdrawn, so ask what happens after regrowth.

The bottom line: deuruxolitinib 8 mg twice daily produced far stronger hair regrowth than 16 mg once daily in this Phase 2 severe alopecia areata trial. That suggests continuous immune-signal control may be critical for waking follicles back up. It is a practical finding that could shape how dermatologists think about JAK-inhibitor dosing for autoimmune hair loss.

Sources

• Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial – PubMed
• ClinicalTrials.gov registration NCT03811912
• Alopecia areata: Emerging therapies and up-to-date management strategies – PubMed